Abstract:Background: Although JAK (Janus Kinase) inhibitors have been widely applied to many types of aggressive tumors with continuously activated JAK/STAT signaling pathways, efficacious compounds against cervical cancer (CC) are still lacking, and chronic exposure to them inevitably results in drug resistance that often arises from compensatory activation of alternative signaling and survival pathways. Therefore, developing novel JAK inhibitors and identifying their partner compounds for combination therapy against CC, remains an unmet clinical need.Methods: In this study, by virtual screening the SPECS database, we selected out multiple JAK inhibitor candidates, validated their kinase activities and antitumor drug efficacies in various biochemical, cellular and in vivo xenograft models. Next, we screened a chemical library containing 2094 small molecules to identify compounds that act synergistically with the best JAK inhibitor obtained above in dampening CC cell propagation. Finally, the molecular mechanism of such synergistic effect was explored.Findings: Twenty potential small-molecule JAK inhibitors were identified by virtual screening, and the top 9 ranking compounds were validated by biochemical assays. AH057, the best JAK inhibitor identified, can effectively block JAK/STAT pathways by directly inhibiting JAK1/2 activities, and exhibits potent antitumor effects including compromised cell proliferation and invasion, increased apoptosis, arrested cell cycles and impaired tumor progression in a xenograft model. Among all cell lines examined, CC cell lines were the most sensitive to AH057. Further, based on the calculated Bliss synergy scores, SGI-1027, a DNMT1 inhibitor, was identified as the best compound that works in high synergy with AH057. The combination of AH057 and SGI-1027 potently induced cell cycle arrest at G1 phase partially through Cyclin D1 and Cyclin A2, and apoptotic cell death that is linked to PARP, Caspase-3, Bcl-xL and Survivin.Interpretation: A novel oral small-molecule JAK1/2 inhibitor AH057 with definitive antitumor efficacy against CC is identified in this study. The combination of AH057 with the DNMT1 inhibitor SGI-1027 synergistically impairs cancer cell propagation via induced apoptosis and cell cycle arrest, likely by acting on a same group of downstream effector molecules that are dually controlled by JAK1/2 and DNMT1. This study provides preclinical support for launching a clinical trial to evaluate the safety and efficacy of this drug combination in patients with CC and other malignant tumors.Funding Statement: This work was supported by grants from the National Key Research and Development Program of China (2016YFA0101201, 2016YFA0100303, 2017YFD0200505), and the National Natural Science Foundation of China (31601103, 31872022).Declaration of Interests: YJW, BK and JZ have a pending patent application titled “Identification of a novel JAK1/2 inhibitor and its synergistic drug combinations against human cancers”. The other authors declared no conflicts of interest.Ethical Approval Statement: The Experimental Animal Ethics Committee of Zhejiang University has approved the animal protocol.

A Novel Small Molecule Compound Displays Preclinical Activity Against Multiple Myeloma by Disrupting the Mtor Signaling Pathway

A Novel Small Molecule Agent Displays Potent Anti-Myeloma Activity by Inhibiting the JAK2-STAT3 Signaling Pathway.

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

Dual Inhibition of Mtorc1/2 by DCZ0358 Induces Cytotoxicity in Multiple Myeloma and Overcomes the Protective Effect of the Bone Marrow Microenvironment

Targeted Inhibition of Mtor by BML-275 Induces Mitochondrial-Mediated Apoptosis and Autophagy in Prostate Cancer.

Polyphyllin I Induces Cell Cycle Arrest and Apoptosis in Human Myeloma Cells Via Modulating Β‐catenin Signaling Pathway

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Identification of a Novel Oral Small-Molecule JAK1/2 Inhibitor and Its Potent Synergistic Drug Combinations Against Cervical Cancer

A Virtual Screen Identified C96 As a Novel Inhibitor of Phosphatidylinositol 3-Kinase That Displays Potent Preclinical Activity Against Multiple Myeloma in Vitro and in Vivo.

A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway

Novel Dual-Targeting C-Myc Inhibitor D347-2761 Represses Myeloma Growth Via Blocking C-Myc/max Heterodimerization and Disturbing Its Stability

Preclinical Activity Of Dcz3301, A Novel Aryl-Guanidino Compound In The Therapy Of Multiple Myeloma

Preclinical Activity of ENMD-981693, an Inhibitor of Aurora A Kinase and Multiple Receptor Tyrosine Kinases, Against Multiple Myeloma (MM) Cells

A Novel Pi3k Inhibitor Identified by A High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

Design, Synthesis and Biological Evaluation of Novel Rapamycin Benzothiazole Hybrids As Mtor Targeted Anti-cancer Agents

SC-535, a novel oral multikinase inhibitor, showed potent antitumor activity in human melanoma models.

The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.

Biochemical, Cellular, and in Vivo Activity of Novel Atp-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin